NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
48 hedge funds and large institutions have $382M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
39.62% more ownership
Funds ownership: 0% → 39.62% (+40%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PS
Peter Svennilson
|
+$230M |
| 2 |
RCP
Rho Capital Partners
New York
|
+$55.1M |
| 3 |
GA
Greenspring Associates
Owings Mills,
Maryland
|
+$23M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$17.7M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$6.9M |
Top Sellers
NGM Hedge Fund Activity: Q2 2019 in Review
48 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2019, worth a combined $382M.
Buyers outnumbered sellers: 48 funds opened new NGM positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Peter Svennilson, opening a new position worth an estimated $230M.
- 48 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $382M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2019.
- 48 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +48 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q2 2019 was Peter Svennilson, an estimated $230M added.
Based on aggregated 13F filings for Q2 2019.